S Nati
- Hematology top 5%
- Hematopoietic Stem Cell Transplantation 9
- Acute Myeloid Leukemia Research 5
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 14
-
- Lymphoma Diagnosis and Treatment 19
- Oncology top 10%
- Cancer Treatment and Pharmacology 4
- Lung Cancer Research Studies 4
- Viral-associated cancers and disorders 4
-
- Acute Lymphoblastic Leukemia research 8
- Co-authors
- Gino SantiniAngelo Michele CarellaE DamasioA CongiuD OcchiniP. CarlierR. VimercatiDomenico Giordano
- Partner nations
- ItalyUnited StatesBrazil
In The Last Decade
S Nati
44 papers receiving 506 citations
Peers
Comparison fields: 5 of 57
- Hematology 216
- Genetics 171
- Pathology and Forensic Medicine 262
- Oncology 244
- Neurology 75
Countries citing papers authored by S Nati
This map shows the geographic impact of S Nati's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Nati with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Nati more than expected).
Fields of papers citing papers by S Nati
This network shows the impact of papers produced by S Nati. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Nati. The network helps show where S Nati may publish in the future.
Co-authorship network
The 25 scholars most cited alongside S Nati, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2013 | 29 | |
| 3 | SAFETY AND EFFICACY OF 90 Y IBRITUMUMAB TIUXETAN (ZEVALIN) FOR UNTREATED FOLLICULAR NON HODGKIN'S LYMPHOMA (FL) PATIENTS. ITALIAN MULTICENTRIC TRIAL. | 2011 | 1 |
| 4 | 2006 | 1 | |
| 5 | 2005 | 41 | |
| 6 | 2004 | 7 | |
| 7 | [Neoplastic residues in the trocar tract in oncologic laparoscopic surgery]. | 2004 | 4 |
| 8 | Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. | 2001 | 24 |
| 9 | 2000 | 20 | |
| 10 | VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group. | 2000 | 11 |
| 11 | 1999 | 7 | |
| 12 | 1998 | 22 | |
| 13 | 1997 | 10 | |
| 14 | 1996 | 29 | |
| 15 | 1991 | 3 | |
| 16 | 1991 | 21 | |
| 17 | 1990 | 3 | |
| 18 | 1989 | 12 | |
| 19 | 1987 | 7 | |
| 20 | 1985 | 32 |
About S Nati
S Nati is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Neurology, having authored 46 papers that have together received 542 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (19 papers), Chronic Lymphocytic Leukemia Research (14 papers), Hematopoietic Stem Cell Transplantation (9 papers), Acute Lymphoblastic Leukemia research (8 papers), Acute Myeloid Leukemia Research (5 papers), Cancer Treatment and Pharmacology (4 papers), Lung Cancer Research Studies (4 papers) and Viral-associated cancers and disorders (4 papers). The work is most often cited by research in Hematology (216 citations), Genetics (171 citations), Pathology and Forensic Medicine (262 citations), Oncology (244 citations) and Neurology (75 citations). S Nati has collaborated with scholars based in Italy, United States and Brazil. Frequent co-authors include Gino Santini, Angelo Michele Carella, E Damasio, A Congiu, D Occhini, P. Carlier, R. Vimercati, Domenico Giordano, Alberto M. Marmont and R Cerri. Their work appears in journals such as Blood, European Journal Of Haematology, Cancer, British Journal of Haematology and BMC Endocrine Disorders.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.